GLP-1/glucagon receptor dual agonists and application thereof
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A GLP-1 and receptor technology, applied in the field of GLP-1/glucagon receptor dual agonists, can solve problems such as failure to be applied
Active Publication Date: 2021-02-26
南京赛诺生物制药有限公司
View PDF36 Cites 3 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
In addition to its blood sugar-raising effect, GCG also has the effects of promoting lipolysis, fat oxidation, and fever in the body (Diabetologia, 2017, 60, 1851–1861). Long-term administration can show weight loss effects by increasing energy metabolism. However, these beneficial effects of GCG on energy metabolism have not been exploited due to their inherent blood sugar-raising effects
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0131] Synthesis of SEQ ID NO:1 polypeptide compound
[0134] Weigh 0.262g (0.1mmol equivalent) of Rink Amide MBHA resin with a loading capacity of 0.382mmol / g, put it into a 25mL reactor, wash the resin once with 7mL of DCM and methanol alternately, and wash the resin twice with 7mL of DCM , then swell the resin with 7 mL of DCM for 1 h, and finally wash the resin 3 times with 7 mL of DMF.
[0135] (2) Removal of resin Fmoc protecting group
[0136] Transfer the swollen resin to PSI200 peptide synthesizer, add 7mL 20% piperidine / DMF (v / v) to react at room temperature for 5min, filter off the deprotection solution, wash the resin once with 7mL DMF, then add 7mL 20% piperidine / DMF (v / v) The deprotection solvent was reacted with the resin fo...
Embodiment 2
[0148] Synthesis of SEQ ID NO:2 polypeptide compound
[0154] The synthesis method was the same as in Example 1, and the target peak was collected and freeze-dried to obtain 0.13 g of the pure product.
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
PUM
Login to view more
Abstract
The invention provides a GLP-1/GCG receptor dual-agonist polypeptide compound. The GLP-1/GCG receptor dual-agonist polypeptide compound provided by the invention can effectively reduce blood sugar, promote weight loss and prevent weight gain, reverse insulin resistance and regulate lipid metabolism. The polypeptide compound provided by the invention has higher agonistic activity on the GLP-1 receptor and the GCG receptor than natural ligands of each receptor, and has lower agonistic activity on a GIP receptor. The polypeptide compound provided by the invention is stable in chemical property, has low immunogenicity features, and is suitable for being used as an active ingredient of medicines for treating metabolic diseases such as diabetes, obesity, hyperlipidemia, NAFLD and NASH.
Description
technical field [0001] The invention relates to biomedicine, in particular to a class of GLP-1 / glucagon receptor dual agonists and applications thereof. Background technique [0002] Obesity and its related metabolic syndrome have become a global public health problem. Many metabolic syndromes such as type 2 diabetes mellitus (T2DM), nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), dyslipidemia Both the incidence and the course of the disease are closely related to obesity. Studies have shown that clinically 80-90% of T2DM patients are overweight or obese, and the use of weight loss therapy is beneficial to the prevention and control of the disease, including controlling blood sugar, reducing morbidity and disability (death) rates, etc. It is generally difficult to achieve the ideal weight loss effect only by exercising and diet control to lose weight. At present, the curative effect of the drugs for treating obesity is relatively limited, and...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to view more 
Login to view more